<2% 的胶质母细胞瘤 (GBM) 病例发生颅外转移。当转移确实发生时，骨骼是最常见的目的地。在此，我们回顾了伴有骨转移的 GBM 患者的临床特征，并评估了潜在的危险因素和预后意义。利用机构数据库，我们识别并回顾性分析了 6 例同时患有 GBM 和骨转移的患者。我们收集了有关患者人口统计、肿瘤遗传学、临床过程和结果的数据。鉴于转移性 GBM 的罕见性，我们利用之前发表的文献进行了历史比较。5 名骨转移患者 (83%) 为男性，诊断 GBM 时的中位年龄为 46 岁（范围：20-84 岁）。所有患者均具有 IDH 野生型、MGMT 启动子非甲基化 GBM，其中 5 名 (83%) 患者的 TP53 发生改变。所有患者均接受 GBM 手术切除，然后接受同步和辅助替莫唑胺放疗。四名患者 (67%) 在骨转移诊断前接受了贝伐单抗治疗。 GBM 诊断后平均 12.2 个月（范围：5.3-35.2）和开始贝伐单抗后 4.8 个月（范围：3.5-13.2）发现骨转移。三名患者（50%）接受了免疫治疗。骨转移诊断后，中位生存期为 25 天（范围：13-225）。在我们的队列中，大多数患者在 GBM 诊断时为男性和年轻人。所有患者均具有 IDH 野生型、MGMT 启动子非甲基化 GBM，并且大多数患者的 TP53 发生改变，这可能对骨转移很重要。大多数患者接受贝伐单抗治疗，这与早期转移有关。 GBM 发生骨转移，预示着已经具有侵袭性的恶性肿瘤的预后不佳。版权所有 © 2024 作者。由 Wolters Kluwer Health, Inc. 出版

Extracranial metastases occur in <2% of cases of glioblastoma (GBM). When metastases do occur, bone is the most common destination. Herein, we review clinical characteristics of GBM patients with osseous metastases and evaluate both potential risk factors and prognostic significance.Using an institutional database, we identified and retrospectively analyzed 6 patients with both GBM and osseous metastases. We collected data on patient demographics, tumor genetics, clinical courses, and outcomes. Given the rarity of metastatic GBM, we conducted historical comparisons using previously published literature.Five patients with osseous metastases (83%) were male, with a median age of 46 years at GBM diagnosis (range: 20-84). All patients had IDH-wildtype, MGMT promoter unmethylated GBM and 5 (83%) had alterations in TP53. All patients underwent surgical resection for GBM followed by radiation with concurrent and adjuvant temozolomide. Four patients (67%) received bevacizumab prior to bone metastasis diagnosis. Bone metastases were discovered at a median of 12.2 months (range: 5.3-35.2) after GBM diagnosis and 4.8 months after starting bevacizumab (range: 3.5-13.2). Three patients (50%) received immunotherapy. After osseous metastasis diagnosis, the median survival was 25 days (range: 13-225).In our cohort, most patients were male and young at the time of GBM diagnosis. All patients had IDH-wildtype, MGMT promoter unmethylated GBM, and most had alterations in TP53, which may be important for osseous metastasis. Most patients received bevacizumab, which has been associated with earlier metastasis. Osseous metastases of GBM occur and portend a dismal prognosis in an already aggressive malignancy.Copyright © 2024 the Author(s). Published by Wolters Kluwer Health, Inc.